134 related articles for article (PubMed ID: 10389653)
61. Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers.
Kohmoto M; Enomoto M; Tamori A; Habu D; Takeda T; Kawada N; Sakaguchi H; Seki S; Shiomi S; Nishiguchi S
J Med Virol; 2005 Feb; 75(2):235-9. PubMed ID: 15602726
[TBL] [Abstract][Full Text] [Related]
62. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment.
Chan HL; Wong VW; Wong GL; Chim AM; Chan HY; Sung JJ
Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1022-6. PubMed ID: 18585971
[TBL] [Abstract][Full Text] [Related]
63. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
[TBL] [Abstract][Full Text] [Related]
64. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
Yaşar DG; Suyanı E; Özenirler S; Sucak GT
Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
[TBL] [Abstract][Full Text] [Related]
65. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
[TBL] [Abstract][Full Text] [Related]
66. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.
Boni C; Bertoletti A; Penna A; Cavalli A; Pilli M; Urbani S; Scognamiglio P; Boehme R; Panebianco R; Fiaccadori F; Ferrari C
J Clin Invest; 1998 Sep; 102(5):968-75. PubMed ID: 9727065
[TBL] [Abstract][Full Text] [Related]
67. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
68. [Hepatitis B virus genotypes and the response to lamivudine therapy].
Zalewska M; Domagała M; Simon K; Gładysz A
Pol Arch Med Wewn; 2005 Dec; 114(6):1190-9. PubMed ID: 16789488
[TBL] [Abstract][Full Text] [Related]
69. [Inhibiting effects of root of Mallotus apelta on duck hepatitis B virus].
Xu S; Lü ZP; Cai HB; Zhang XG; Liu Q; Tan Y
Zhong Xi Yi Jie He Xue Bao; 2006 May; 4(3):285-8. PubMed ID: 16696917
[TBL] [Abstract][Full Text] [Related]
70. Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
Seehofer D; Rayes N; Neuhaus R; Berg T; Müller AR; Bechstein WO; Neuhaus P
Transpl Int; 2000; 13 Suppl 1():S359-62. PubMed ID: 11112032
[TBL] [Abstract][Full Text] [Related]
71. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
72. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus.
Chen RY; Bowden S; Desmond PV; Dean J; Locarnini SA
J Gastroenterol Hepatol; 2003 Jun; 18(6):630-7. PubMed ID: 12753143
[TBL] [Abstract][Full Text] [Related]
73. [Antiviral effect of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic mice].
Xiao SR; Xu GD; Wei WJ; Peng B; Deng YB
Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):17-22. PubMed ID: 29804357
[No Abstract] [Full Text] [Related]
74. Comparison of the 48-week efficacy of Lamivudine plus Adefovir or Entecavir monotherapy in patients with HBeAg negative hepatitis following Lamivudine treatment failure.
Zhang Q; Zhang L; Xing Y; Qin Y; Liu G
Acta Gastroenterol Belg; 2019; 82(1):31-34. PubMed ID: 30888751
[TBL] [Abstract][Full Text] [Related]
75. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.
Seo YS; Kim JH; Yeon JE; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH
World J Gastroenterol; 2007 Aug; 13(30):4072-9. PubMed ID: 17696224
[TBL] [Abstract][Full Text] [Related]
76. [Lamivudine treatment consensus from relative experts in 2003].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2003 Aug; 11(8):497-9. PubMed ID: 12939188
[No Abstract] [Full Text] [Related]
77. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
78. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
[TBL] [Abstract][Full Text] [Related]
79. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
[TBL] [Abstract][Full Text] [Related]
80. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children.
Shapira R; Mor E; Bar-Nathan N; Sokal EM; Tur-Kaspa R; Dinari G; Ben-Ari Z
Transplantation; 2001 Jul; 72(2):333-6. PubMed ID: 11477362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
